The most successful treatment for multiple myeloma today is a four-drug combination therapy that pairs a targeted antibody with three older backbone drugs, followed by a stem cell transplant when possible, and then long-term maintenance medication. No single drug cures myeloma on its own. The best outcomes come from a sequenced treatment plan that layers several therapies across months and years. The five-year relative survival rate for myeloma now stands at 62.4%, a figure that has climbed steadily as newer drug combinations have entered standard practice.
Quadruplet Therapy Is the New Standard
For decades, the go-to first treatment was a three-drug regimen combining a proteasome inhibitor, an immunomodulatory drug, and a steroid. That triplet worked well, but adding a fourth drug, an antibody called daratumumab that locks onto a protein on myeloma cells, has proven significantly better. Multiple large clinical trials, including CASSIOPEIA, GRIFFIN, PERSEUS, and CEPHEUS, have confirmed this advantage, and quadruplet therapy is now considered the standard of care for newly diagnosed patients.
The CEPHEUS trial, published in Nature Medicine, offers a clear picture of the difference. After nearly five years of follow-up, 81.2% of patients on the four-drug regimen achieved a complete response or better, compared with 61.6% on the three-drug version. The risk of the cancer progressing or of death was 43% lower with the quadruplet. Just as important, 60.9% of patients on the four-drug combination reached a state where no detectable cancer remained at an extremely sensitive testing threshold, versus 39.4% on three drugs.
The induction phase typically runs for three to four cycles, with each cycle lasting three to four weeks. Your oncologist will monitor your response throughout, adjusting if needed before moving to the next treatment phase.
Why Minimal Residual Disease Matters
Oncologists increasingly measure treatment success not just by whether tumors shrink, but by whether cancer cells become undetectable at the molecular level. This is called minimal residual disease (MRD) negativity, and it means that even when scanning through a million bone marrow cells, no myeloma cells are found. Reaching this level of response is the strongest predictor of how long the cancer stays away.
Patients who achieve MRD negativity with a good overall response have a median progression-free survival of 51 months, compared to 26 months for those who remain MRD positive. When that MRD-negative state lasts 24 months or longer, the outlook improves even further. In multivariate analysis, MRD positivity was the single strongest risk factor for disease progression, with roughly 2.6 times the risk compared to MRD-negative patients. This is why the newer quadruplet regimens, which drive MRD negativity rates above 60%, represent such a meaningful advance.
Stem Cell Transplant After Induction
For patients healthy enough to tolerate it (generally those under 70 or in good overall condition), an autologous stem cell transplant follows induction therapy. This involves collecting your own stem cells, receiving high-dose chemotherapy to wipe out remaining myeloma, and then reinfusing the stored stem cells to rebuild your bone marrow. It remains one of the most effective single interventions for extending remission.
In a survival analysis of transplant recipients, the one-year progression-free survival was 90%, and three-year progression-free and overall survival rates were both 76.7%. Transplant doesn’t work for everyone, and patients who are ineligible due to age or other health conditions still benefit substantially from extended drug therapy using the same quadruplet regimens.
Maintenance Therapy Doubles Remission Time
After induction (and transplant, if applicable), maintenance therapy keeps the cancer suppressed for as long as possible. The standard approach uses lenalidomide, an immunomodulatory pill taken daily in 28-day cycles and continued until the disease returns or side effects become intolerable. This phase can last years.
The Myeloma XI trial demonstrated just how much maintenance matters. Among transplant-eligible patients, those on lenalidomide maintenance had a median progression-free survival of 57 months, compared to 30 months for those who simply waited and watched. For transplant-ineligible patients, the gap was 26 months versus 11 months. In both groups, maintenance roughly doubled the time before the cancer came back.
CAR-T Cell Therapy for Relapsed Disease
When myeloma returns after initial treatment, a newer class of immunotherapy called CAR-T cell therapy has produced some of the highest response rates ever seen in heavily treated patients. This approach involves removing your T cells (a type of immune cell), engineering them in a lab to recognize a protein on myeloma cells, and infusing them back into your body. Two CAR-T products are approved for myeloma, and they differ meaningfully in potency.
In a large international comparison, ciltacabtagene autoleucel (cilta-cel) achieved an overall response rate of 93%, with 48% of patients reaching a complete response within just 30 days of infusion. The other approved product, idecabtagene vicleucel (ide-cel), had a 79% overall response rate with 26% complete responses at day 30. Both are reserved for patients who have already received multiple prior treatments, but cilta-cel is increasingly being studied in earlier treatment lines because of its exceptional response depth.
Bispecific Antibodies: A Growing Option
Three bispecific antibodies are now FDA-approved for myeloma that has relapsed or stopped responding to other therapies. These are off-the-shelf drugs (no custom manufacturing required, unlike CAR-T) that work by physically bridging your T cells to myeloma cells, forcing an immune attack. Two of them, teclistamab and elranatamab, target the same protein that CAR-T therapies recognize. The third, talquetamab, targets a different protein entirely, which makes it useful when the cancer has already been exposed to treatments aimed at that first target.
Overall response rates in clinical trials ranged from 61% to 68% across the three drugs. These numbers are in patients who had already failed a median of several prior treatment lines, making those response rates notable. Among responders, the duration of response was encouraging: 18.4 months for teclistamab, and not yet reached (meaning most patients were still responding) for elranatamab at the time of analysis. These drugs are given as ongoing injections under the skin, typically on a weekly or biweekly schedule.
Antibody-Drug Conjugates for Heavily Treated Patients
For patients who have exhausted many options, antibody-drug conjugates offer another mechanism. Belantamab mafodotin delivers a cell-killing payload directly to myeloma cells by hitching it to an antibody that seeks out the same surface protein targeted by CAR-T and bispecific therapies. In a real-world study of patients who had received a median of six prior treatment lines, the overall response rate was 43%, with a median duration of response of 10.5 months and a median overall survival of 17.2 months. Even among patients previously exposed to other therapies targeting the same protein, 29% still responded.
How These Treatments Fit Together
The reason myeloma outcomes have improved so dramatically is not any single breakthrough but the layering of treatments in sequence. A typical successful treatment journey looks like this: quadruplet induction therapy for roughly three to four months, stem cell transplant for eligible patients, then years of lenalidomide maintenance. When the cancer eventually returns, patients move to second-line drug combinations. If those fail, CAR-T therapy, bispecific antibodies, and antibody-drug conjugates each offer meaningful chances of response. Each layer buys additional time, and many patients cycle through several treatment lines over the course of years.
The overall picture is one where myeloma remains incurable for most people but increasingly manageable as a long-term condition. Patients diagnosed today have access to treatment sequences that simply did not exist a decade ago, and the depth of responses, particularly the rising rates of MRD negativity, suggests that a subset of patients may achieve remissions lasting many years.